Lupus nephritis. How latest insights into its pathogenesis promote novel therapies

Current Opinion in Rheumatology

Volumn 24, Issue 5, 2012, Pages 457-465

  Kulkarni, Onkar P ^a   Anders, Hans Joachim ^a  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ABATACEPT; ALPHA ACTININ; ALPHA INTERFERON; ATACICEPT; AZATHIOPRINE; B CELL MATURATION ANTIGEN; BELIMUMAB; BETA INTERFERON; BORTEZOMIB; CYCLOPHOSPHAMIDE; EPITHELIAL DERIVED NEUTROPHIL ACTIVATING FACTOR 78; EPRATUZUMAB; GAMMA INTERFERON INDUCIBLE PROTEIN 10; HYDROXYCHLOROQUINE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G3; INTERFERON REGULATORY FACTOR 7; INTERLEUKIN 17; LIPOCORTIN 2; MONOCYTE CHEMOTACTIC PROTEIN 1; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PLACEBO; PROTEIN MDM2; RITUXIMAB; SIFALIMUMAB; STEROID; TABALUMAB; TOCILIZUMAB; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

ADD ON THERAPY; ANTIGEN SPECIFICITY; APOPTOSIS; AUTOIMMUNITY; B LYMPHOCYTE; CHROMATIN; CROSS REACTION; CYTOKINE RELEASE; DENDRITIC CELL; DNA METHYLATION; DRUG EFFICACY; DRUG MEGADOSE; GENE OVEREXPRESSION; GENETIC VARIABILITY; HUMAN; IMMUNOPATHOGENESIS; KERATINOCYTE; KIDNEY INJURY; LUPUS ERYTHEMATOSUS NEPHRITIS; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; LYMPHOCYTE PROLIFERATION; MEMBRANOUS GLOMERULONEPHRITIS; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; SYMPTOM; TH17 CELL; VIRUS IMMUNITY; VIRUS INFECTION; VIRUS PARTICLE;

AUTOIMMUNITY; B-LYMPHOCYTES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMMUNOTHERAPY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES;

EID: 84864884467     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0b013e328354c877     Document Type: Review

References (80)

1. Goodnow CC. Multistep pathogenesis of autoimmune disease. Cell 2007; 130:25-35.
2. Hom G, Graham RR, Modrek B, et al. Association of systemic lupus erythematosus with C8orf13-BLK and ITGAM-ITGAX. N Engl J Med 2008; 358:900-909.
3. Migliorini A, Anders HJ. A novel pathogenetic concept-antiviral immunity in lupus nephritis. Nat Rev Nephrol 2012; 8:183-189.
4. Saxena R, Mahajan T, Mohan C. Lupus nephritis: current update. Arthritis Res Ther 2011; 13:240.
5. Munoz LE, Lauber K, Schiller M, et al. The role of defective clearance of apoptotic cells in systemic autoimmunity. Nat Rev Rheumatol 2010; 6:280-289.
6. Mortensen ES, Rekvig OP. Nephritogenic potential of anti-DNA antibodies against necrotic nucleosomes. J Am Soc Nephrol 2009; 20:696-704.
7. Savarese E, Chae OW, Trowitzsch S, et al. U1 small nuclear ribonucleoprotein immune complexes induce type I interferon in plasmacytoid dendritic cells through TLR7. Blood 2006; 107:3229-3234.
8. Savarese E, Steinberg C, Pawar RD, et al. Requirement of Toll-like receptor 7 for pristane-induced production of autoantibodies and development of murine lupus nephritis. Arthritis Rheum 2008; 58:1107-1115.
9. Lau CM, Broughton C, Tabor AS, et al. RNA-associated autoantigens activate B cells by combined B cell antigen receptor/Toll-like receptor 7 engagement. J Exp Med 2005; 202:1171-1177.
10. Lech M, Kulkarni OP, Pfeiffer S, et al. Tir8/Sigirr prevents murine lupus by suppressing the immunostimulatory effects of lupus autoantigens. J Exp Med 2008; 205:1879-1888.
11. Lech M, Skuginna V, Kulkarni OP, et al. Lack of SIGIRR/TIR8 aggravates hydrocarbon oil-induced lupus nephritis. J Pathol 2010; 220:596-607.
12. Leadbetter EA, Rifkin IR, Hohlbaum AM, et al. Chromatin-IgG complexes activate B cells by dual engagement of IgM and Toll-like receptors. Nature 2002; 416:603-607.
13. Guiducci C, Gong M, Xu Z, et al. TLR recognition of self nucleic acids hampers glucocorticoid activity in lupus. Nature 2010; 465:937-941.
14. Patole PS, Zecher D, Pawar RD, et al. G-rich DNA suppresses systemic lupus. J Am Soc Nephrol 2005; 16:3273-3280.
15. Pawar RD, Ramanjaneyulu A, Kulkarni OP, et al. Inhibition of Toll-like receptor-7 (TLR-7) or TLR-7 plus TLR-9 attenuates glomerulonephritis and lung injury in experimental lupus. J Am Soc Nephrol 2007; 18:1721-1731.
16. Teichmann LL, Ols ML, Kashgarian M, et al. Dendritic cells in lupus are not required for activation of T and B cells but promote their expansion, resulting in tissue damage. Immunity 2010; 33:967-978.
17. Chan OT, Hannum LG, Haberman AM, et al. A novel mouse with B cells but lacking serum antibody reveals an antibody-independent role for B cells in murine lupus. J Exp Med 1999; 189:1639-1648.
18. Allam R, Sayyed SG, Kulkarni O, et al. Murine double minute-2 drives systemic lupus erythematosus and lupus nephritis. J Am Soc Nephrol 2011; 22:2016-2027.
19. Lech M, Weidenbusch M, Kulkarni O, et al. IRF4 deficiency abrogates lupus nephritis despite enhancing systemic cytokine production. J Am Soc Nephrol 2011; 22:1443-1452.
20. Jacob N, Stohl W. Autoantibody-dependent and autoantibody-independent roles for B cells in systemic lupus erythematosus: past, present, and future. Autoimmunity 2010; 43:84-97.
21. Tojo T, Friou GJ. Lupus nephritis: varying complement-fixing properties of immunoglobulin G antibodies to antigens of cell nuclei. Science 1968; 161:904-906.
22. Sekine H, Ruiz P, Gilkeson GS, et al. The dual role of complement in the progression of renal disease in NZB/W F(1) mice and alternative pathway inhibition. Mol Immunol 2011; 49:317-323.
23. Sekine H, Kinser TT, Qiao F, et al. The benefit of targeted and selective inhibition of the alternative complement pathway for modulating autoimmunity and renal disease in MRL/lpr mice. Arthritis Rheum 2011; 63:1076-1085.
24. Bao L, Haas M, Quigg RJ. Complement factor H deficiency accelerates development of lupus nephritis. J Am Soc Nephrol 2011; 22:285-295.
25. Yu F, Wu LH, Tan Y, et al. Tubulointerstitial lesions of patients with lupus nephritis classified by the 2003 International Society of Nephrology and Renal Pathology Society system. Kidney Int 2010; 77:820-829.
26. Nowling TK, Gilkeson GS. Mechanisms of tissue injury in lupus nephritis. Arthritis Res Ther 2011; 13:250.
27. Yung S, Cheung KF, Zhang Q, Chan TM. Anti-dsDNA antibodies bind to mesangial annexin II in lupus nephritis. J Am Soc Nephro 2010; 21:1912-1927.
28. Hakkim A, Furnrohr BG, Amann K, et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci USA 2010; 107:9813-9818.
29. Kaplan MJ, Villanueva E, Yalavarthi S, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011; 187:538-552.
30. Garcia-Romo GS, Caielli S, Vega B, et al. Netting neutrophils are major inducers of type I IFN production in pediatric systemic lupus erythematosus. Sci Transl Med 2011; 3:73ra20.
31. Lande R, Ganguly D, Facchinetti V, et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci Transl Med 2011; 3:73ra19.
32. Villanueva E, Yalavarthi S, Berthier CC, et al. Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 2011; 187:538-552.
33. Bosch X. Systemic lupus erythematosus and the neutrophil. N Engl J Med 2011; 365:758-760.
34. Hedberg A, Fismen S, Fenton KA, et al. Heparin exerts a dual effect on murine lupus nephritis by enhancing enzymatic chromatin degradation and preventing chromatin binding in glomerular membranes. Arthritis Rheum 2011; 63:1065-1075.
35. Niederer HA, Clatworthy MR, Willcocks LC, et al. FcgammaRIIB, FcgammaRIIIB, and systemic lupus erythematosus. AnnNY Acad Sci 2010; 1183:69-88.
36. Allam R, Lichtnekert J, Moll A, et al. Viral RNA and DNA sense common antiviral responses including type I interferons in mesangial cells. J Am Soc Nephrol 2009; 20:1086-1096.
37. Fluer K, Allam R, Zecher D, et al. Viral RNA induces type I interferondependent cytokine release and cell death in mesangial cells via MDA5. Implications for viral infection-associated glomerulonephritis. Am J Pathol 2009; 175:2014-2022.
38. Hagele H, Allam R, Pawar RD, et al. Double-stranded RNA activates type I interferon secretion in glomerular endothelial cells via retinoic acid-inducible gene (RIG)-1. Nephrol Dial Transplant 2009; 24:3312-3318.
39. Hagele H, Allam R, Pawar RD, et al. Double-stranded DNA activates glomerular endothelial cells and enhances albumin permeability via a Toll-like receptor-independent cytosolic DNA recognition pathway. Am J Pathol 2009; 175:1896-1904.
40. Fairhurst AM, Xie C, Fu Y, et al. Type I interferons produced by resident renal cells may promote end-organ disease in autoantibody-mediated glomerulonephritis. J Immunol 2009; 183:6831-6838.
41. Anders HJ, Lichtnekert J, Allam R. Interferon-alpha and-beta in kidney inflammation. Kidney Int 2010; 77:848-854.
42. Triantafyllopoulou A, Franzke CW, Seshan SV, et al. Proliferative lesions and metalloproteinase activity in murine lupus nephritis mediated by type I interferons and macrophages. Proc Natl Acad Sci USA 2010; 107:3012-3017.
43. Anders HJ, Vielhauer V, Eis V, et al. Activation of Toll-like receptor-9 induces progression of renal disease in MRL-Fas(lpr) mice. FASEB J 2004; 18:534-536.
44. Rich SA. Human lupus inclusions and interferon. Science 1981; 213:772-775.
45. Yung S, Cheung KF, Zhang Q, et al. AntidsDNA antibodies bind to mesangial annexin II in lupus nephritis. J Am Soc Nephrol 2010; 21:1912-1927.
46. Zhao Z, Deocharan B, Scherer PE, et al. Differential binding of cross-reactive anti-DNA antibodies to mesangial cells: the role of alpha-actinin. J Immunol 2006; 176:7704-7714.
47. Mjelle JE, Rekvig OP, Van Der Vlag J, et al. Nephritogenic antibodies bind in glomeruli through interaction with exposed chromatin fragments and not with renal cross-reactive antigens. Autoimmunity 2011; 44:373-383.
48. Fenton KA, Tommeras B, Marion TN, et al. Pure antidsDNA mAbs need chromatin structures to promote glomerular mesangial deposits in BALB/c mice. Autoimmunity 2010; 43:179-188.
49. Allam R, Anders HJ. The role of innate immunity in autoimmune tissue injury. Curr Opin Rheumatol 2008; 20:538-544.
50. Wang Y, Ito S, Chino Y, et al. Laser microdissection-based analysis of cytokine balance in the kidneys of patients with lupus nephritis. Clin Exp Immunol 2010; 159:1-10.
51. Deban L, Russo RC, Sironi M, et al. Regulation of leukocyte recruitment by the long pentraxin PTX3. Nat Immunol 2010; 11:328-334.
52. Lech M, Rommele C, Kulkarni OP, et al. Lack of the long pentraxin PTX3 promotes autoimmune lung disease but not glomerulonephritis in murine systemic lupus erythematosus. PLoS One 2011; 6:e20118.
53. Clark MR, Chang A, Henderson SG, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol 2011; 186:1849-1860.
54. Neusser MA, Lindenmeyer MT, Edenhofer I, et al. Intrarenal production of Bcell survival factors in human lupus nephritis. Mod Pathol 2011; 24:98-107.
55. Espeli M, Bokers S, Giannico G, et al. Local renal autoantibody production in lupus nephritis. J Am Soc Nephrol 2011; 22:296-305.
56. Chang A, Henderson SG, Brandt D, et al. In situ B cell-mediated immune responses and tubulointerstitial inflammation in human lupus nephritis. J Immunol 2011; 186:1849-1860.
57. Bekar KW, Owen T, Dunn R, et al. Prolonged effects of short-term anti-CD20 B cell depletion therapy in murine systemic lupus erythematosus. Arthritis Rheum 2010; 62:2443-2457.
58. Ramanujam M, Bethunaickan R, Huang W, et al. Selective blockade of BAFF for the prevention and treatment of systemic lupus erythematosus nephritis in NZM2410 mice. Arthritis Rheum 2010; 62:1457-1468.
59. Apostolidis SA, Crispin JC, Tsokos GC. IL-17-producing T cells in lupus nephritis. Lupus 2011; 20:120-124.
60. Bethunaickan R, Berthier CC, Ramanujam M, et al. A unique hybrid renal mononuclear phagocyte activation phenotype in murine systemic lupus erythematosus nephritis. J Immunol 2011; 186:4994-5003.
61. Katsiari CG, Liossis SN, Sfikakis PP. The pathophysiologic role of monocytes and macrophages in systemic lupus erythematosus: a reappraisal. Semin Arthritis Rheum 2010; 39:491-503.
62. Kulkarni OP, RyuM, Kantner C, et al. Recombinant chaperonin 10 suppresses cutaneous lupus and lupus nephritis in MRL-(Fas)lpr mice. Nephrol Dial Transplant 2012; 27:1358-1367.
63. Smeets B, Kuppe C, Sicking EM, et al. Parietal epithelial cells participate in the formation of sclerotic lesions in focal segmental glomerulosclerosis. J Am Soc Nephrol 2011; 22:1262-1274.
64. Smeets B, Angelotti ML, Rizzo P, et al. Renal progenitor cells contribute to hyperplastic lesions of podocytopathies and crescentic glomerulonephritis. J Am Soc Nephrol 2009; 20:2593-2603.
65. Smeets B, Uhlig S, Fuss A, et al. Tracing the origin of glomerular extracapillary lesions from parietal epithelial cells. J Am Soc Nephrol 2009; 20:2604-2615.
66. Croca SC, Rodrigues T, Isenberg DA. Assessment of a lupus nephritis cohort over a 30-year period. Rheumatology (Oxford) 2011; 50:1424-1430.
67. Clowse ME,Magder L, Witter F, et al. Hydroxychloroquine in lupus pregnancy. Arthritis Rheum 2006; 54:3640-3647.
68. Pons-Estel GJ, Alarcon GS, McGwin G Jr, et al. Protective effect of hydroxychloroquine on renal damage in patients with lupus nephritis: LXV, data from a multiethnic US cohort. Arthritis Rheum 2009; 61:830-839.
69. Houssiau FA, Vasconcelos C, D'Cruz D, et al. The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 2010; 69:61-64.
70. Kulkarni OP, Sayyed SG, Kantner C, et al. 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice. Am J Pathol 2010; 176:2840-2847.
71. Wang HY, Cui TG, Hou FF, et al. Induction treatment of proliferative lupus nephritis with leflunomide combined with prednisone: a prospective multicentre observational study. Lupus 2008; 17:638-644.
72. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the lupus nephritis assessment with rituximab (LUNAR) study. Arthritis Rheum 2012; 64:1215-1226.
73. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum 2010; 62:222-233.
74. Weidenbusch M, Römmele C, Schrö ttle A, et al. Beyond the LUNAR trial. Efficacy of rituximab in refractory lupus nephritis. Nephrol Dial Transplant 2012 (in press).
75. Navarra SV, Guzman RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011; 377:721-731.
76. Merrill JT, Burgos-Vargas R, Westhovens R, et al. The efficacy and safety of abatacept in patients with nonlife-threatening manifestations of systemic lupus erythematosus: results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2010; 62:3077-3087.
77. Merrill JT, Wallace DJ, Petri M, et al. Safety profile and clinical activity of sifalimumab, a fully human antiinterferon alpha monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis 2011; 70:1905-1913.
78. Ichikawa HT, Conley T, Muchamuel T, et al. Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells. Arthritis Rheum 2012; 64:493-503.
79. Neubert K, Meister S, Moser K, et al. The proteasome inhibitor bortezomib depletes plasma cells and protects mice with lupus-like disease from nephritis. Nat Med 2008; 14:748-755.
80. Aringer M, Burkhardt H, Burmester GR, et al. Current state of evidence on 'off label' therapeutic options for systemic lupus erythematosus, including biological immunosuppressive agents, in Germany, Austria, and Switzerland-a consensus report. Lupus 2011; 21:386-401.